Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries Limited American Depositary Shares
(NY:
TEVA
)
34.22
-0.11 (-0.32%)
Official Closing Price
Updated: 7:00 PM EST, Feb 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Teva Pharmaceutical Industries Limited American Depositary Shares
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
32
33
Next >
Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims
June 12, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape
↗
June 12, 2023
The FDA is actively seeking new suppliers to address the shortages of methotrexate, a widely used cancer drug in short supply since March. Methotrexate is an injected medication utilized to treat...
Via
Benzinga
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
June 12, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Why Teva Pharmaceutical Stock Is Jumping Today
↗
May 18, 2023
Investors are reacting positively to Teva's new growth strategy.
Via
The Motley Fool
Teva Pharma Crumbles After First-Quarter Earnings Miss, Flat Sales
↗
May 10, 2023
Teva reported absolutely flat sales in the first quarter and light earnings.
Via
Investor's Business Daily
Teva Pharmaceutical Clocks Lower Profits On Flat Q1 Sales, Sticks To Annual Guidance
↗
May 10, 2023
Via
Benzinga
Teva Pharmaceutical Indus: Q1 Earnings Insights
↗
May 10, 2023
Via
Benzinga
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
June 12, 2023
From
Alvotech
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
June 09, 2023
Via
Benzinga
Is AbbVie or Amgen the Better Bargain Buy Right Now?
↗
June 08, 2023
These elite drugmakers are both working through a number of headwinds.
Via
The Motley Fool
Teva Concludes Nationwide Opioids Settlement Agreement
June 08, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management
June 06, 2023
From
Phil Inc.
Via
Business Wire
Teva Pharmaceuticals Just Made a Big Announcement, but Is It a Buy?
↗
June 05, 2023
It's unclear whether the pivot will be enough to halt its recent decline.
Via
The Motley Fool
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
June 02, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
May 25, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023
↗
May 25, 2023
Via
Benzinga
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting
May 20, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
↗
May 18, 2023
Via
Benzinga
Why Is Alimera Sciences (ALIM) Stock Up 21% Today?
↗
May 18, 2023
Alimera Sciences (ALIM) stock is taking off on Thursday after signing a major deal with EyePoint Pharmaceuticals (EYPT).
Via
InvestorPlace
Why Is Teva Pharmaceuticals (TEVA) Stock Up Today?
↗
May 18, 2023
Teva Pharmaceuticals (TEVA) stock is climbing higher on Thursday after the pharmaceutical company announced a new growth strategy.
Via
InvestorPlace
Netflix, Synopsys, Madison Square Garden Entertainment And Other Big Stocks Moving Higher On Thursday
↗
May 18, 2023
U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some big stocks recording gains in today’s session. Urstadt Biddle Properties Inc. (NYSE: UBP) shares surged...
Via
Benzinga
Teva Launches New “Pivot to Growth” Strategy
May 18, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Apple Thwarts $2B In Fraud Transactions, UBS Takes $17B Hit From 'Hasty Credit Suisse Takeover,' Verizon Streamlines Unlimited Data Plans: Today's Top Stories
↗
May 17, 2023
Benzinga
Via
Benzinga
One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps
↗
May 17, 2023
AstraZeneca Plc (NASDAQ: AZN) has decided to leave a U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), making it the third company to leave the group in the last...
Via
Benzinga
A Bitter Pill to Swallow: Teva's $235M Challenge to GSK Dismissed by Supreme Court
↗
May 15, 2023
The U.S.
Via
Benzinga
AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S.
May 15, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
May 12, 2023
Via
Benzinga
Teva Pharmaceutical Industries (TEVA) Q1 2023 Earnings Call Transcript
↗
May 10, 2023
TEVA earnings call for the period ending March 31, 2023.
Via
The Motley Fool
Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
May 10, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Nasdaq, S&P 500 Futures Slip Ahead Of Inflation Data — But Analyst Hints It Still Might Be Ok To Be Bullish
↗
May 10, 2023
Via
Benzinga
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.